SMB·BIO

Inside Lotte Biologics' Songdo Plant 1: Raw materials flow downward by gravity from 15 stories up

by
Choi Eun-ji
Published : Nov. 19, 2026 - 10:00:00
    • Copy Completed!

View Korean Original

Vertical layout assigns each floor a distinct role, from media preparation to cell culture and purification, minimizing energy use and cell damage

State-of-the-art automated analyzers and electronic lab notebooks linked in real time to the Syracuse, New York facility

Syracuse-Songdo 'dual site' now operational as company eyes cumulative orders of $1.9 billion in its fifth year

Lotte Biologics' Plant 1 at the Songdo Bio Campus in Incheon. [Lotte Biologics]
Lotte Biologics' Plant 1 at the Songdo Bio Campus in Incheon. [Lotte Biologics]

The defining feature of Lotte Biologics' Plant 1 at the Songdo Bio Campus in Incheon's Songdo International City is a vertically integrated design: raw materials introduced at the top floor travel downward through each successive level entirely under gravity, without any mechanical pumping, and emerge at the bottom as finished drug substance.

Lotte Biologics opened the facility to the media for the first time Wednesday, following a completion ceremony at the Songdo Bio Campus. The five-story building, which rises to the height of a 14- to 15-story apartment block, assigns a distinct process role to each floor.

The fourth floor, visited first, serves as the hub for research and development and quality control. Inside the cell culture laboratory, cells received from client companies are thawed and revived, and process development work was under way using automated culture equipment — the Ambr system — alongside 10-liter benchtop bioreactors, with teams working to identify optimal conditions for temperature, oxygen and other parameters.

An adjacent purification laboratory and pilot facility housed 100-liter and 500-liter bioreactors and purification equipment that replicate commercial-scale production at a reduced size.

Lotte Biologics' Plant 1 at the Songdo Bio Campus in Incheon. [Lotte Biologics]
Lotte Biologics' Plant 1 at the Songdo Bio Campus in Incheon. [Lotte Biologics]

The quality analysis laboratory sets itself apart from competitors through automation built on the latest equipment and real-time data integration with the company's Syracuse campus in the United States. Rather than having staff process large volumes of samples by hand, the facility uses a Liquid Handler — an automated sample pre-treatment system — to deliver consistent, error-free analytical results even at high throughput.

The laboratory also concentrates an array of advanced precision instruments: a liquid chromatography-mass spectrometer (LC-MS) for detailed analysis of the complex protein structures of antibody drugs, an inductively coupled plasma mass spectrometer (ICP-MS) for tracing trace elements, and a surface plasmon resonance (SPR) analyzer for evaluating the binding affinity and function of molecules.

All experimental procedures are recorded and stored in an electronic lab notebook (ELN) to ensure data integrity. Analytical equipment and data are internally linked with the Syracuse factory, enabling immediate technology transfer and quality exchange between the two sites.

Lotte Biologics' Plant 1 at the Songdo Bio Campus in Incheon. [Lotte Biologics]
Lotte Biologics' Plant 1 at the Songdo Bio Campus in Incheon. [Lotte Biologics]

Descending to the third floor — the heart of the factory — eight 15,000-liter stainless steel bioreactors dominate the space, their upper piping rising through a double-height ceiling. Cells validated on the fourth floor pass through 120-liter, 600-liter and 3,000-liter seed bioreactors on the third floor before entering the final 15,000-liter vessels, where large-scale culture reaches a combined capacity of 120,000 liters.

Culture media and buffers prepared on the fifth floor — the top level — flow down by gravity to feed the third-floor bioreactors. Once culture is complete, the bulk drug substance moves further down: through a second-floor harvest process that separates impurities, then through first-floor purification, before being stored in cold rooms maintained at between minus 70 and minus 20 degrees Celsius.

Jeong Woo-cheong, head of the EPC (engineering, procurement and construction) division at Lotte Biologics, said the top-down gravity-flow approach was chosen over mechanical conveyance to prevent cell damage that can occur during pump transfer and to maximize energy efficiency. "We have also introduced equipment capable of running high-titer and standard products in parallel, an unmanned automated warehouse with roughly 6,000 storage cells, and autonomous driving sample-transport robots," Jeong said.

A press briefing held immediately after the completion ceremony gave a first public look at the company's survival strategy as a late entrant and its medium- to long-term roadmap.

Jeon Ji-won, head of strategy planning, said the company's two-track approach — simultaneously acquiring the Syracuse factory in the United States and building Plant 1 in Songdo after its 2022 launch — had paid off. "In our fifth year of operation, we expect cumulative orders to reach as much as $1.9 billion this year," Jeon said.

At full capacity, Plant 1 is expected to produce more than 6,000 kilograms of antibody drugs annually, generating sales of around 700 billion won ($523 million). To support that output, the company is hiring and training a workforce of about 1,000 direct employees, including more than 800 biotech specialists.

Synergies with the Syracuse campus in the United States, which has a 40,000-liter capacity, are also taking shape. Following its acquisition, the Syracuse facility achieved a 99.2 percent employment retention rate and has since recorded a 99 percent batch success rate and secured more than 62 approvals from global regulatory agencies. In September, it received zero observations during an unannounced inspection by the US Food and Drug Administration.

Once a purification process scale-up at Syracuse is completed in January, the company's "dual site" competitiveness will be further strengthened — linking a North American forward base capable of handling everything from antibody drug substance production to antibody-drug conjugate (ADC) conjugation with Songdo as a large-scale commercial production hub.

Attendees pose at the completion ceremony for Plant 1 at the Lotte Biologics Songdo Bio Campus in Yeonsu-gu, Incheon, on Wednesday. From left: Tamatsu Ken-ichi, CEO of Lotte Holdings; Jung Il-young, National Assembly member for Incheon Yeonsu-gu B; Shin Yu-yeol, CEO of Lotte Biologics; Park Chan-dae, Incheon mayor; Shin Dong-bin, chairman of Lotte Group; Song Young-gil, National Assembly member for Incheon Yeonsu-gu A; Noh Jun-hyeong, CEO of Lotte Holdings; Kim Jong-cheol, head of the Incheon Free Economic Zone Authority; and Park James, co-CEO of Lotte Biologics. [Lotte Biologics]
Attendees pose at the completion ceremony for Plant 1 at the Lotte Biologics Songdo Bio Campus in Yeonsu-gu, Incheon, on Wednesday. From left: Tamatsu Ken-ichi, CEO of Lotte Holdings; Jung Il-young, National Assembly member for Incheon Yeonsu-gu B; Shin Yu-yeol, CEO of Lotte Biologics; Park Chan-dae, Incheon mayor; Shin Dong-bin, chairman of Lotte Group; Song Young-gil, National Assembly member for Incheon Yeonsu-gu A; Noh Jun-hyeong, CEO of Lotte Holdings; Kim Jong-cheol, head of the Incheon Free Economic Zone Authority; and Park James, co-CEO of Lotte Biologics. [Lotte Biologics]

When asked how Lotte Biologics plans to differentiate itself from established contract development and manufacturing organization (CDMO) players, executives pointed to speed and customized flexibility. Park Min-su, head of global business development, said being a new entrant was an advantage: "We are not bound by existing conventions, which means we can respond quickly to what customers need." Jeon added that the company was drawing on a customer-centric philosophy honed in retail and services to position itself as a "PR-DMO" — a partner-type CDMO that anticipates and resolves clients' development challenges before they arise. Park James, the company's CEO, is scheduled to present this strategy in person at the JP Morgan Healthcare Conference in January.

Lotte Biologics expects revenue to begin flowing from next year through technology transfers, pilot production runs and manufacturing for regulatory submissions. Full commercial production and a return to profitability are projected for 2028, after regulatory approvals are secured. The timing of ground-breaking for Plants 2 and 3 at Songdo will be decided flexibly, based on future order trends and Plant 1's utilization rate.


silverpaper@heraldcorp.com
This content was produced with the assistance of AI translation services.

MOST READ